No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

byBryan SunandMinjee Kim

May 21, 2024

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Click here to read this study in The New England Journal of Medicine.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy

#VisualAbstract: Thrombectomy Plus Medical Care Resulted in Better Functional Outcomes and Lower Mortality than Medical Care Alone in Patients with Stroke with a Large Infarct

RelatedReports

Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)

Cardiology

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

October 14, 2025

StudyGraphics

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

August 22, 2025

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

Cardiology

Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy

August 14, 2025

StudyGraphics

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

August 8, 2025

Intravascular ultrasound-guided stent insertion improves outcomes in patients with acute coronary syndrome

#VisualAbstract: Ponatinib is Superior to Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Intrathecal gene therapy as a treatment for giant axonal neuropathy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy

#VisualAbstract: Thrombectomy Plus Medical Care Resulted in Better Functional Outcomes and Lower Mortality than Medical Care Alone in Patients with Stroke with a Large Infarct

Intravascular ultrasound-guided stent insertion improves outcomes in patients with acute coronary syndrome

RelatedReports

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

Intravascular ultrasound-guided stent insertion improves outcomes in patients with acute coronary syndrome

#VisualAbstract: Ponatinib is Superior to Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Intrathecal gene therapy as a treatment for giant axonal neuropathy

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits